ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2024
Human intestinal microbiome: Role in health and disease.
Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global research trends in stroke and gut microbiota: a multi-database bibliometric analysis and cross-validation study.Frontiers in microbiology · 2026Pooled it
- An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2025Pooled it
- Cannabigerol at the Interface of the Gut Microbiota and EndoCannabinoidome: Mechanistic Insights into Inflammation and Pain Modulation.Medical sciences (Basel, Switzerland) · 2026Review
- Microbiota-Targeted Chitooligosaccharides Intervention Restores Glucose Homeostasis After Islet Cell Transplantation in Rapamycin-Treated Mice.Food science & nutrition · 2026Article
- Boron as a Molecular Architect of Host-Microbiome Symbiosis: Implications for Dysbiosis and Aging-Related Pathologies.Life (Basel, Switzerland) · 2026Review
- Gut microbiota and metabolites in acute lung injury: mechanisms and therapeutic perspectives.Respiratory research · 2026Review
- Gut microbiota-derived metabolites in gastrointestinal cancer: immunomodulatory mechanisms via the tryptophan-AhR axis and translational perspectives.Frontiers in immunology · 2026Review
- Molecular Mechanisms of the Microbiota-Gut-Brain Axis in the Onset and Progression of Stroke.International journal of molecular sciences · 2025Review
- Review
- The Bidirectional Relationship Between FGIDs and Anxiety: Pathophysiological Mechanisms and New Therapeutic Strategies.Actas espanolas de psiquiatria · 2025Review
- Neonatal hypoxia leads to impaired intestinal function and changes in the composition and metabolism of its microbiota.Scientific reports · 2025Article
- Matrix Dynamics and Microbiome Crosstalk: Matrix Metalloproteinases as Key Players in Disease and Therapy.International journal of molecular sciences · 2025Review
- Intestinal Microbiota Dysbiosis Role and Bacterial Translocation as a Factor for Septic Risk.International journal of molecular sciences · 2025Review
- Nutritional Habits in Crohn's Disease Onset and Management.Nutrients · 2025Review
- Exploring gut microbiota and spinal cord injury: pathogenesis, treatment strategies and prospects.Frontiers in immunology · 2025Review
- Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer.Frontiers in pharmacology · 2025Article
- Long-term effects of altitude on changes in intestinal flora in a young and middle-aged population: a longitudinal analysis before and after 6 months of entry to high altitude.Frontiers in microbiology · 2025Article
- Editorial: Fecal Microbiota Transplants: challenges in translating microbiome research to clinical applications.Frontiers in microbiology · 2025Article
- Mechanistic study on the restoration of intestinal barrier integrity and alleviation of inflammatory bowel disease by rhynchophylline via the AhR-NR4A1 pathway.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study of the microbiota and the microbiome, and specifically the intestinal one, has determined great interest due to the possible association of their alterations with numerous diseases. These include entities as diverse as Crohn's disease, autism, diabetes, cancer or situations as prevalent today as obesity. In view of this situation, different recommendations have been performed regarding the use of probiotics, prebiotics, and postbiotics as modulators of the microbiota and the microbiome, seeking both preventive and therapeutic effects, and faecal material transfer (FMT) is proposed as an alternative. The latter has emerged as the only proven beneficial intervention on the intestinal microbiome, specifically in the treatment of recurrent colitis associated with Clostridioides difficile (R-CDI). In the rest of the entities, the lowering of laboratory costs has favored the study of the microbiome, which is resolved by delivering reports with catalogs of microorganisms, metabolites or supposed biomarkers without consensus on their composition associated with healthy or diseased microbiota and the disease. There is still insufficient evidence in any disease for interventions on the microbiome beyond FMT and R-CDI. Multi- and multi-disciplinary work with extensive research and the application of artificial intelligence in this field may shed light on the questions raised currently. Ethical issues must also be resolved in light of possible interventions within the umbrella of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.